HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Folliguet, T. A. Articles by Laborde, F. Search for Related Content PubMed PubMed Citation Articles by Folliguet, T. A. Articles by Laborde, F. Related Collections Valve disease

Ann Thorac Surg 2001;71:S289-S292
© 2001 The Society of Thoracic Surgeons

---

Bioprosthetic valves and conduits: new developments

Pericarbon pericardial bioprosthesis: an experience based on the lessons of the past

^a L’Institut Mutualiste Montsouris, Paris, France

Address reprint requests to Dr Folliguet, L’Institut Mutualiste Montsouris, 46 Boulevard Jourdan, 75014 Paris, France
e-mail: thierry.folliguet{at}imm.fr

Presented at the VIII International Symposium on Cardiac Bioprostheses, Cancun, Mexico, Nov 3–5, 2000.

Background. The Pericarbon pericardial bioprosthesis, at the time of its creation, showed a breakthrough in terms of low calcification deposit rate, absence of valvular tears, and durability. The purpose of this study was to evaluate results after 10 years.

Methods. From September 1988 to December 1997, 277 patients received a total of 287 Pericarbon pericardial valves. There were 224 (80.8%) isolated aortic valve replacements (AVR), 39 isolated mitral valve replacements (MVR), 1 tricuspid valve replacement, 3 pulmonary valve replacements, and 10 aortic and mitral valve replacements. The total cumulative follow-up was 1,221.42 patient-years (mean 4.9 ± 2.6 years).

Results. Overall hospital mortality was 10.1%. The overall patient survival at 10.8 years was 55.8% ± 4.2%, for AVR it was 60.0% ± 4.5%, and for MVR it was 46.5% ± 11.9%. The freedom from valve-related death for the overall population at 10.8 years was 98.0% ± 1.0%, for AVR 97.6% ± 1.1%, and for MVR 100%. The overall freedom from structural valve deterioration was 96.6% ± 2.4%, for AVR 96.1% ± 2.7%, and for MVR 100%. The overall freedom from embolic events was 96.0% ± 1.5%, for AVR 96.0% ± 1.6%, and for MVR 100%. The overall freedom from reoperation was 88.1% ± 3.8%, for AVR 89.9% ± 4.2%, and for MVR 80.6% ± 7.3%.

Conclusions. These results show that over a period of up to 10 years, the Pericarbon pericardial bioprosthesis is an excellent and safe valve substitute. Developing a detoxification process aimed at improving the biological behavior of the glutaraldehyde-tanned valve may increase those advantages.

This article has been cited by other articles:

				F. Botzenhardt, W. B. Eichinger, S. Bleiziffer, R. Guenzinger, I. M. Wagner, R. Bauernschmitt, and R. Lange Hemodynamic Comparison of Bioprostheses for Complete Supra-Annular Position in Patients With Small Aortic Annulus J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2054 - 2060. [Abstract] [Full Text] [PDF]